目的 探討清肺消炎丸聯(lián)合布地奈德福莫特羅吸入粉霧劑治療慢性阻塞性肺疾病的臨床療效。方法 選取2020年2月—2021年6月新鄉(xiāng)市第一人民醫(yī)院收治的126例慢性阻塞性肺疾病患者，按照隨機數(shù)字表法分為對照組和治療組，各包括63例。對照組吸入布地奈德福莫特羅吸入粉霧劑（Ⅱ），1吸/次，2次/d。治療組患者在對照組基礎(chǔ)上口服清肺消炎丸，5 g/次，3次/d。兩組患者連續(xù)治療8周。觀察兩組的臨床療效，比較兩組肺通氣功能、自我評估測試量表（CAT）評分和血清炎癥因子水平。結(jié)果 治療后，治療組總有效率（93.65%）高于對照組（80.95%）（P<0.05）。治療后，兩組的最大呼氣中期流量（MMEF）、第1秒鐘用力呼氣容積占用力肺活量的百分比（FEV1/FVC）、第1秒用力呼氣容積占預(yù)計值的百分比（FEV1% pred）顯著升高（P<0.05）；治療后，治療組的MMEF、FEV1/FVC、FEV1% pred高于對照組，差異有統(tǒng)計學意義（P<0.05）。治療后，兩組的CAT評分明顯降低（P<0.05）；治療組的CAT評分低于對照組，差異有統(tǒng)計學意義（P<0.05）。治療后，兩組的基質(zhì)金屬蛋白酶-9（MMP-9）、轉(zhuǎn)化生長因子-β₁（TGF-β₁）、C反應(yīng)蛋白（CRP）水平顯著降低（P<0.05）；治療后，治療組的MMP-9、TGF-β₁、CRP水平低于對照組，差異有統(tǒng)計學意義（P<0.05）。結(jié)論 清肺消炎丸聯(lián)合布地奈德福莫特羅吸入粉霧劑可提高慢性阻塞性肺疾病的臨床療效，改善肺通氣功能，降低血清炎癥因子，治療安全性良好。

Objective To investigate the clinical efficacy of Qingfei Xiaoyan Pills combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of chronic obstructive pulmonary disease. Methods Patients (126 cases) with chronic obstructive pulmonary disease in Xinxiang First People’s Hospital from February 2020 to June 2021 were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation (Ⅱ), 1 suction/time, twice daily. Patients in the treatment group were po administered with Qingfei Xiaoyan Pills on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and pulmonary ventilation function, CAT score, and serum inflammatory factors levels in two groups were compared. Results After treatment, the total effective rate of the treatment group (93.65%) was higher than that of the control group (80.95%) (P<0.05). After treatment, the MMEF, FEV1/FVC, and FEV1%pred were significantly increased in two groups (P<0.05). After treatment, the MMEF, FEV1/FVC, and FEV1% pred in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the CAT scores of two groups were significantly decreased (P<0.05). After treatment, the CAT score of the treatment group was lower than that of the control group (P<0.05). After treatment, the level of MMP-9, TGF-β₁, and CRP in two groups were significantly decreased (P<0.05). After treatment, the levels of MMP-9, TGF-β₁, and CRP in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qingfei Xiaoyan Pills combined with Budesonide and Formoterol Fumarate Powder for inhalation can improve the curative effect of chronic obstructive pulmonary disease, improve pulmonary function, and reduce airway inflammatory reaction, with good safety.

R974

河南省醫(yī)學科技攻關(guān)計劃聯(lián)合共建項目（2018020853）